Investing.com - Financial Markets Worldwide

SAB Biotherapeutics Inc (SABS)

NASDAQ
Currency in USD
3.700
+0.060(+1.65%)
Closed·
After Hours
3.698-0.002(-0.05%)
·

SABS Income Statement

Period Ending:
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa1.32
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-40.94%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa30.25
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-28.93
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-102.64%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-2,187.62%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa13.98
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-42.91
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-12.7%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-3,244.87%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa0.97
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+258.79%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.32
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa1.29
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa7.81
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-34.13
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-34.11
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+19.17%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-2,579.03%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa-
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-34.11
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-34.11
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+19.17%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-2,579.03%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-34.11
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-3.68
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+51.81%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-3.68
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+51.81%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa9.26
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa9.26
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-38.12
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-11.03%
EBITDA Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-2,882.46%
EBIT
aa.aaaa.aaaa.aaaa.aaaa.aa-42.91
* In Millions of USD (except for per share items)

FAQ

What was SAB Biotherapeutics’s revenue at year end?

At the end of the last reported fiscal year, SAB Biotherapeutics (SABS) recorded total revenue of 1.322.

What was SAB Biotherapeutics’s net income for the year?

For the full year, SAB Biotherapeutics reported net income of -34.105.

How much net income did SAB Biotherapeutics post in the last quarter?

In the most recent quarter, SAB Biotherapeutics (SABS) posted net income of 45.45.

What was SAB Biotherapeutics’s gross profit for the year?

Gross profit for the year was reported at -28.929.

How much gross profit did SAB Biotherapeutics generate last quarter?

SAB Biotherapeutics recorded gross profit of -0.490 in its latest quarterly report.

What was SAB Biotherapeutics’s annual operating income?

For the full year, SAB Biotherapeutics (SABS) reported operating income of -42.911.

What was SAB Biotherapeutics’s operating income last quarter?

Quarterly operating income was -12.679.

What was SAB Biotherapeutics’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -11.914.

What was the quarter-over-quarter change in EBITDA for SAB Biotherapeutics?

EBITDA changed by -33.000% compared to the last quarter.

What was the quarter-over-quarter change in gross profit for SAB Biotherapeutics?

In the latest quarter, gross profit changed by -107.022% from the previous quarter.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.